SU011248
Sponsors
Pfizer, M.D. Anderson Cancer Center, Massachusetts General Hospital, AstraZeneca, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions
AdultBladder CancerBreast NeoplasmsCarcinoma, Renal CellColorectal CarcinomaColorectal NeoplasmsGastrointestinal Stromal TumorGastrointestinal Stromal Tumors
Phase 1
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
CompletedNCT00137436
Start: 2005-10-31End: 2010-03-31Updated: 2011-08-29
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
CompletedNCT00174434
Start: 2005-09-30End: 2007-08-31Updated: 2009-01-27
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
TerminatedNCT00361244
Start: 2006-07-31End: 2010-08-31Updated: 2017-02-17
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
CompletedNCT00372853
Start: 2006-11-30End: 2010-05-31Updated: 2012-06-06
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
CompletedNCT00790595
Start: 2006-06-30Updated: 2012-07-31
Phase 2
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
CompletedNCT00078000
Start: 2004-03-31End: 2005-11-30Updated: 2008-11-26
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
CompletedNCT00077974
Start: 2004-02-29End: 2008-09-30Updated: 2010-10-13
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
CompletedNCT00077987
Start: 2003-12-31End: 2005-04-30Target: 84Updated: 2007-01-11
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
CompletedNCT00137449
Start: 2005-09-30End: 2008-04-30Updated: 2009-09-15
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
CompletedNCT00246571
Start: 2006-01-31End: 2011-06-30Updated: 2012-07-12
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
TerminatedNCT00330564
Start: 2006-05-31End: 2011-05-31Updated: 2024-06-27
SU011248 in Advanced Hepatocellular Carcinoma
CompletedNCT00361309
Start: 2006-04-30End: 2009-03-31Updated: 2014-03-18
Efficacy of SU 011248 in Head And Neck Carcinoma
TerminatedNCT00408252
Start: 2007-02-28End: 2011-12-31Updated: 2019-09-19
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
CompletedNCT00578526
Start: 2008-04-30End: 2014-07-16Updated: 2018-08-22
Phase 3
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
CompletedNCT00075218
Start: 2003-12-31End: 2008-05-31Updated: 2009-09-28
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
CompletedNCT00083889
Start: 2004-08-31End: 2008-09-30Updated: 2010-01-26
Unknown Phase
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
CompletedNCT00443534
Start: 2006-05-31End: 2011-12-31Updated: 2013-05-24
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
CompletedNCT00531544
Start: 2007-02-28End: 2012-06-30Updated: 2016-01-05